BerGenBio ASA: Information about the last exercise period for Warrants issued in connection with rights issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, INCANADA,JAPAN, AUSTRALIA OR THE UNITED STATES, OR ANY OTHER JURISDICTION IN WHICH SUCHRELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOESNOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. PLEASE SEETHE IMPORTANT NOTICE AT THE END OF THIS ANNOUNCEMENT.

Bergen, Norway, 3 April 2024 - Reference is made to the stock exchangeannouncement from BerGenBio ASA (the "Company") dated 2 April 2024 regardingthecommencement of the last exercise period for the Warrants issued in connectionwith the rights issue in June 2023 (the "Warrants").

Information about the last exercise period for the Warrants, 2 April 2024 - 15April 2024 at 16:30 (CEST), including how to exercise the Warrants and a Q&Asection is available on the Company'swebsite: https://www.bergenbio.com/investors/investor-relations/warrants

A Norwegian translation is available at the Company'swebsite: https://www.bergenbio.com/investors/investor-relations/norwegian-warrants

Exercise of Warrants electronically through the VPS online subscription systemis now working after some issues yesterday. Instruction how to exercise isavailable at the Company's website.

The last exercise period for the Warrants ends on 15 April 2024 at 16:30(CEST).

Carnegie AS and Arctic Securities AS are acting as managers in connection withthe exercise of Warrants (jointly the "Managers").

For further information, please contact:

Martin Olin CEO, BerGenBio ASA

ir@bergenbio.no

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Media Relations

Jan Lilleby

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developingtransformative drugs targeting AXL as a potential cornerstone of therapy foraggressive diseases, including cancer and severe respiratory infections. TheCompany is focused on its proprietary lead candidate bemcentinib a potentiallyfirst-in-class selective AXL inhibitor in development for STK11 mutated NSCLCand severe respiratory infections. BerGenBio is based in Bergen, Norway with asubsidiary in Oxford, UK. The Company is listed on the Oslo Stock Exchange(ticker: BGBIO). For more information, visit www.bergenbio.com.

- IMPORTANT INFORMATION -

This announcement does not constitute an offer of securities for sale or asolicitation of an offer to purchase securities of the Company in the UnitedStates or any other jurisdiction. The securities of the Company may not beoffered or sold in the United States absent registration or an exemption fromregistration under the U.S. Securities Act of 1933, as amended (the"U.S.Securities Act"). The securities of the Company have not been, and willnotbe, registered under the U.S. Securities Act. Any sale in the United States ofthe securities mentioned in this communication will be made solely to"qualifiedinstitutional buyers" as defined in Rule 144A under the U.S. Securities Act.Nopublic offering of the securities will be made in the United States.

This announcement has been prepared on the basis that any offer of securitiesinany Member State of the European Economic Area, other than Norway, which hasimplemented the Prospectus Regulation (EU) (2017/1129, as amended, the"Prospectus Regulation") (each, a "Relevant Member State") will be madepursuantto an exemption under the Prospectus Regulation, as implemented in thatRelevantMember State, from the requirement to publish a prospectus for offers ofsecurities. Accordingly any person making or intending to make any offer inthatRelevant Member State of securities which are the subject of the offeringcontemplated in this announcement, may only do so in circumstances in which noobligation arises for the Company or any of the Managers to publish aprospectuspursuant to Article 3 of the Prospectus Regulation or supplement a prospectuspursuant to Article 16 of the Prospectus Regulation, in each case, in relationto such offer.

In the United Kingdom, this announcement is only addressed to and is onlydirected at Qualified Investors who (i) are investment professionals fallingwithin Article 19(5) of the Financial Services and Markets Act 2000 (FinancialPromotion) Order 2005 (as amended) (the "Order") or (ii) are persons fallingwithin Article 49(2)(a) to (d) of the Order (high net worth companies,unincorporated associations, etc.) (all such persons together being referredtoas "Relevant Persons"). This announcement are directed only at RelevantPersonsand must not be acted on or relied on by persons who are not Relevant Persons.Any investment or investment activity to which this announcement relates isavailable only to Relevant Persons and will be engaged in only with RelevantPersons. Persons distributing this communication must satisfy themselves thatitis lawful to do so.

Matters discussed in this announcement may constitute forward-lookingstatements. Forward-looking statements are statements that are not historicalfacts and may be identified by words such as "anticipate", "believe","continue", "estimate", "expect", "intends", "may", "should", "will" andsimilarexpressions. The forward-looking statements in this release are based uponvarious assumptions, many of which are based, in turn, upon furtherassumptions.Although the Company believes that these assumptions were reasonable whenmade,these assumptions are inherently subject to significant known and unknownrisks,uncertainties, contingencies and other important factors which are difficultorimpossible to predict and are beyond its control. Such risks, uncertainties,contingencies and other important factors could cause actual events to differmaterially from the expectations expressed or implied in this release by suchforward-looking statements. The information, opinions and forward-lookingstatements contained in this announcement speak only as at its date, and aresubject to change without notice.

This announcement is made by and, and is the responsibility of, the Company.TheManagers are acting exclusively for the Company and no one else and will notberesponsible to anyone other than the Company for providing the protectionsafforded to their respective clients, or for advice in relation to thecontentsof this announcement or any of the matters referred to herein.

Neither the Managers nor any of their respective affiliates makes anyrepresentation as to the accuracy or completeness of this announcement andnoneof them accepts any responsibility for the contents of this announcement oranymatters referred to herein.

This announcement is for information purposes only and is not to be relieduponin substitution for the exercise of independent judgment. It is not intendedasinvestment advice and under no circumstances is it to be used or considered asan offer to sell, or a solicitation of an offer to buy any securities or arecommendation to buy or sell any securities of the Company. Neither theManagers nor any of their respective affiliates accepts any liability arisingfrom the use of this announcement. Any offering of the securities referred tointhis announcement will be made by means of a prospectus.

This announcement is an advertisement and is not a prospectus for the purposesof the Prospectus Regulation. Investors should not subscribe for anysecuritiesreferred to in this announcement except on the basis of information containedinthe Prospectus dated 26 May 2023 and stock exchange announcements published inconnection with the Rights Issue and the Warrants. Copies of the Prospectus isavailable from the Company's registered office and, subject to certainexceptions, on the websites of the Company(www.bergenbio.com/investors/investor-relations/warrants), (Carnegie www.carnegie.no/ongoing-prospectuses-and-offerings) and Arctic Securities AS (www.arctic.com/offerings).

Each of the Company, the Managers and their respective affiliates expresslydisclaims any obligation or undertaking to update, review or revise anystatement contained in this announcement whether as a result of newinformation,future developments or otherwise.

The distribution of this announcement and other information may be restrictedbylaw in certain jurisdictions. Persons into whose possession this announcementorsuch other information should come are required to inform themselves about andto observe any such restrictions.

This information is published in accordance with the requirements of theContinuing Obligations.

https://newsweb.oslobors.no/message/614943